Mirikizumab, Mirikizumab
I6T-MC-AMAP
Phase 3 small_molecule active
Quick answer
Mirikizumab, Mirikizumab for Ulcerative Colitis is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Ulcerative Colitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active